CH3 BioSystems
Private Company
Total funding raised: $2.5M
Overview
CH3 BioSystems is a private, early-revenue biotechnology company founded in 2015, specializing in synthetic biology and metabolic research tools centered on epigenetic regulation, specifically protein methylation. The company operates a hybrid business model, selling proprietary research reagents (like its flagship ANTI-mRG antibody) and cell lines directly to academic and corporate researchers while pursuing a long-term vision of discovering novel drug and diagnostic candidates. Its strategy is to use its platform to first serve the research tools market, generating revenue and validating its technology, to ultimately identify and commercialize its own therapeutic programs. Leadership consists of scientific co-founders, indicating a strong research-driven culture.
Technology Platform
Patent-protected platform centered on protein arginine methylation biology, featuring a flagship monoclonal antibody (ANTI-mRG) designed to recognize methylated proteins, supported by a suite of related molecular tools including expression vectors, cell lines, enzymes, and peptides for epigenetic research and discovery.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
CH3 BioSystems competes in the research tools segment against large, diversified suppliers like Thermo Fisher Scientific, Abcam, and Merck Millipore, as well as smaller niche players. Its differentiation is its specialized focus on protein methylation. In the nascent therapeutic methylation space, it would compete with biopharma companies developing PRMT inhibitors and other epigenetic therapies, though it is currently at a much earlier stage.